Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report published on Tuesday,Benzinga reports. They currently have a $23.00 target price on the stock.

Separately, HC Wainwright began coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They issued a “buy” rating and a $20.00 target price on the stock. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $20.40.

Artiva Biotherapeutics Trading Down 2.7 %

ARTV stock opened at $3.54 on Tuesday. Artiva Biotherapeutics has a 12 month low of $3.37 and a 12 month high of $17.31. The firm has a 50-day moving average of $4.78 and a two-hundred day moving average of $9.29.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ARTV. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at $42,000. China Universal Asset Management Co. Ltd. purchased a new position in Artiva Biotherapeutics during the 4th quarter valued at about $52,000. Wells Fargo & Company MN grew its position in Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after acquiring an additional 3,361 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in Artiva Biotherapeutics during the third quarter worth about $135,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Artiva Biotherapeutics during the third quarter worth about $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.